Combining blood pressure drug with dietary-resistant starch may help stave off diabetic kidney disease

Combining a low dose of blood pressure medication with a higher intake of dietary-resistant starch might help stave off diabetic kidney disease, according to results from a new animal study. Kidney disease is a common diabetes complication and the leading cause of end-stage kidney failure. Researchers will present their work this week at the American Physiology Summit, the flagship annual meeting of the American Physiological Society (APS), in Long Beach, California. 

Although blood pressure medicines have been shown to protect kidney function, high doses can cause dehydration, very low blood pressure and electrolyte imbalance. 

"Our study suggests that combining dietary interventions with a low dose of established medications for diabetic kidney disease management can provide a more feasible and lower side-effect alternative for patients to implement and improve their health outcomes by helping maintain their kidney integrity," said Claudia Carrillo, a PhD student at Iowa State University, who performed the research. 

Dietary-resistant starch is found in unripe bananas, cooked and cooled potatoes, legumes and whole grains. This type of carbohydrate isn't digested in the small intestine like most foods. Instead, it ferments in the large intestine, where it feeds beneficial gut bacteria. 

Carrillo's research team previously showed that giving rat models of Type 1 and Type 2 diabetes a diet high in resistant starch-;where 35% to 50% of their carbohydrates were from resistant starch-;prevented symptoms of declining kidney function. Although these results were promising, a dietary intervention requiring so much resistant starch is not practical. 

In this new study, we wanted to explore a dietary intervention that was more feasible to implement for diabetic patients in their daily lives. We opted to combine this dietary intervention at a lower dosage than before-;equivalent to 5 to 10% of consumed carbohydrates from resistant starch-;with low-dose renin-angiotensin system inhibitor, a blood pressure medication that had been shown to elicit the same effect on kidney health." 

Claudia Carrillo, PhD student at Iowa State University

The researchers found that compared to the control groups rat models of Type 2 diabetes that consumed low-to-moderate amounts of resistant starch while also receiving blood pressure medication showed restored vitamin D blood levels and decreased loss of vitamin D and protein in the urine, which are symptoms of kidney deterioration seen during diabetes progression. The study results, together with gene and protein expression analyses, also showed that the combined intervention imparted a protective effect on the kidney by modulating the renal renin-angiotensin system. This critical hormonal system helps regulate blood pressure and fluid balance in the body. 

"Our research provides more information toward understanding diabetes complications, especially related to kidney health," Carrillo said. "This work could be used to investigate possible translatable strategies that use a whole food source and already well-used medication to minimize the risk for these complications." 

The researchers are getting ready to begin a related study that will use Type 1 diabetic rats to find out if the results seen with Type 2 diabetes animals differ in an insulin-deficient model. They also plan to explore how other types of fiber, such as whole oats, might affect kidney health, and they want to study the microbiome's role in the drug-diet intervention. 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer